BioDrone Therapeutics Inc. was incorporated in Seattle, WA in 2019 to facilitate the global business development for BioDrone® platform technology developed by MDimune Inc. To expedite the commercialization of BioDrone® technology with enormous therapeutic potentials, the company is currently focused on two key activities. First, BioDrone Therapeutics is actively seeking advanced technologies in diverse therapeutic areas that can be integrated into BioDrone® platform. Next, the company is exploring partnership opportunities with global pharmaceutical companies to extend the therapeutic applications of BioDrone® platform technology.
MDimune Inc. is a biotech company headquartered in Seoul, Korea. Founded in 2015, MDimune has been dedicated to the development of innovative therapeutic platform called BioDrone®. BioDrone® platform technology is a novel technology that uses cell-derived vesicles to achieve highly target-specific drug delivery. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. MDimune’s current focus includes cancer, COPD, OA and other rare diseases. MDimune is actively pursuing business partnerships with biotech, pharmaceuticals, and hospitals for the potential application of the BioDrone® technology in various unmet medical needs.
BioDrone® is an innovative drug delivery platform technology that relies on tiny vesicles obtained from diverse cell sources, called cell-derived vesicles (CDVs), by using the proprietary extrusion method.
Copyright © 2020 BioDrone Therapeutics Inc. - All Rights Reserved.